NCT04468061 2026-02-27
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
Dana-Farber Cancer Institute
Phase 2 Recruiting
Clinical Trials
5 trialsNCT06963905 2026-02-17
SIMONE
Yale University
Phase 1/2 Recruiting
NCT04454437 2026-02-02
Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments
Gilead Sciences
Phase 2 Active not recruiting
NCT06926920 2026-01-30
A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
Gilead Sciences
Phase 1/2 Recruiting
NCT05633654 2026-01-20
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Gilead Sciences
Phase 3 Recruiting